• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom shares steady after posting Street-beating Q1 earnings

May 1, 2019 By Fink Densford

Dexcom updated logo

Shares in Dexcom (NSDQ:DXCM) are steady in after-hours trading today after the diabetes-focused device maker posted first quarter 2019 earnings that topped loss-per-share and sales expectations.

The San Diego-based company posted losses of $26.9 million, or 30¢ per share, on sales of $280.5 million for the three months ended March 31, seeing losses grow 11.2% while sales grew a significant 52.1% compared with the same period during the previous year.

After adjusting to exclude one-time items, losses per share were 5¢, well ahead of the 16¢ loss-per-share consensus on Wall Street. Analysts also expected to see sales of approximately $246.4 million, which the company topped by more than $30 million.

“Dexcom is off to a great start in 2019, with our growth testifying to the rising awareness and excitement around real-time CGM and Dexcom’s new G6 technology. Given the strength of our performance thus far, we are pleased to raise our full-year growth outlook,” prez & CEO Kevin Sayer said in a press release.

Dexcom updated its guidance for the full fiscal year 2019, now expecting to see sales of between $1.25 billion and $1.3 billion with a non-GAAP operating margin of approximately 6%.

Shares in Dexcom fell 2% today to $118.62 before posting its earnings, and have not moved in after-hour trading as of 4:26 p.m. EDT.

In February, Dexcom said that it won Health Canada approval for its G6 continuous glucose monitoring system for people with diabetes ages two and up.

Filed Under: Business/Financial News, Diabetes, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS